Aemetis (NASDAQ:AMTX) Earns Buy Rating from HC Wainwright

Aemetis (NASDAQ:AMTX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $28.00 price objective on the specialty chemicals company’s stock.

Separately, Ascendiant Capital Markets lowered their price objective on shares of Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Aemetis has an average rating of “Moderate Buy” and a consensus price target of $12.95.

Aemetis Price Performance

Shares of AMTX opened at $2.63 on Monday. The firm has a fifty day moving average price of $3.30 and a 200 day moving average price of $2.99. The stock has a market cap of $130.80 million, a PE ratio of -1.16 and a beta of 1.35. Aemetis has a 1-year low of $2.10 and a 1-year high of $7.03.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million during the quarter, compared to analysts’ expectations of $77.79 million. During the same period in the previous year, the firm posted ($0.59) earnings per share. As a group, equities analysts expect that Aemetis will post -2.02 EPS for the current fiscal year.

Institutional Trading of Aemetis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Aemetis by 68.2% during the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock worth $52,000 after purchasing an additional 9,137 shares during the last quarter. Hutchinson Capital Management CA purchased a new stake in Aemetis in the 2nd quarter valued at about $70,000. Barclays PLC increased its stake in shares of Aemetis by 274.6% during the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after acquiring an additional 34,816 shares during the last quarter. Rhumbline Advisers grew its holdings in Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after purchasing an additional 50,528 shares during the period. Finally, Geode Capital Management LLC increased its position in Aemetis by 7.7% during the third quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company’s stock worth $2,126,000 after purchasing an additional 66,031 shares during the last quarter. 27.02% of the stock is owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.